SCHEMBL248343

SCHEMBL248343

CC(C)(C)N(C(=O)O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 3/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
AR P10275 1/20 0.41
MAPT P10636 1/20 0.41
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK3 Q15120 1/20 0.40
PDK4 Q16654 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ASPH Q12797 1/20 0.40
KDM8 Q8N371 1/20 0.40
CYP1A2 P05177 1/20 0.40
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248344 1.00 NPSR1 (0.44) NPSR1ALDH1A1HTTHSD17B10TDP1
SCHEMBL2080613 0.83 ALDH1A1 (0.47) NPSR1ALDH1A1HTTHSD17B10TDP1
SCHEMBL9210396 0.82 ALDH1A1 (0.43) NPSR1ALDH1A1HTTHSD17B10TDP1
SCHEMBL17556135 0.79 KIF18A (0.46) NPSR1ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL652038 0.79 HCAR3 (0.44) ALDH1A1HTTL3MBTL1MEN1KMT2A
SCHEMBL652037 0.79 HCAR3 (0.44) ALDH1A1HTTL3MBTL1MEN1KMT2A
SCHEMBL17556134 0.79 KIF18A (0.46) NPSR1ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL601391 0.78 ATM (0.46) ALDH1A1HSD17B10TDP1TSHRL3MBTL1
SCHEMBL601392 0.78 ATM (0.46) ALDH1A1HSD17B10TDP1TSHRL3MBTL1
SCHEMBL2219445 0.78 AKR1C3 (0.46) ALDH1A1MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266822-B2 Solid forms of tacedinaline THE BROAD INSTITUTE, INC. (US) 2016-02-23 US disclosed
US-8841346-B2 Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-09-23 US disclosed
US-20140275268-A1 NOVEL SOLID FORMS OF TACEDINALINE THE BROAD INSTITUTE, INC. (US) 2014-09-18 US disclosed
US-8729130-B2 Methods of using novel solid forms of tacedinaline THE BROAD INSTITUTE, INC. (US) 2014-05-20 US disclosed
US-8563615-B2 Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-10-22 US disclosed
US-20130150450-A1 NOVEL SOLID FORMS OF TACEDINALINE THE BROAD INSTITUTE, INC. (US) 2013-06-13 US disclosed
US-20130102677-A1 NOVEL SOLID FORMS OF TACEDINALINE THE BROAD INSTITUTE, INC. (US) 2013-04-25 US disclosed
US-20120322879-A1 USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2012-12-20 US disclosed
EP-2493298-A1 THE USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS Massachusetts Institute of Technology (US) 2012-09-05 EP disclosed
WO-2012003413-A1 NOVEL SOLID FORMS OF TACEDINALINE THE BROAD INSTITUTE, INC. (US) 2012-01-05 WO disclosed
US-20110224303-A1 USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS MASSACHUSETTS GENERAL HOSPITAL 2011-09-15 US disclosed
WO-2011053876-A1 THE USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322879-A1 USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS CHRNA4, SLC6A4, CHRNB4 NPSR1 96/4885ALDH1A1 1595/4885HTT 1356/4885
US-20110224303-A1 USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS CHRNA4, SLC6A4, CHRNB4 NPSR1 96/4885ALDH1A1 1595/4885HTT 1356/4885
US-20130102677-A1 NOVEL SOLID FORMS OF TACEDINALINE ACSS2, SLC10A1, ACAT2 NPSR1 2782/4885ALDH1A1 3839/4885HTT 2263/4885
US-20130150450-A1 NOVEL SOLID FORMS OF TACEDINALINE ACSS2, SLC10A1, ACAT2 NPSR1 2782/4885ALDH1A1 3839/4885HTT 2263/4885
US-20140275268-A1 NOVEL SOLID FORMS OF TACEDINALINE ACSS2, FAM162A, ACAT2 NPSR1 2972/4885ALDH1A1 3973/4885HTT 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.